u/akavaev

Reddit r/wallstreetbets
· tracked since May 2026
Calls
1
Win Rate
100.0%
return
+2.1%
Calls 1 1 Posts tracked · 0.0/day
Calls
7d 0
30d 0
90d 0
Win Rate 100% Long 1 Short 0
Win Rate
7d 0%
30d 0%
90d 100%
Average Return +2.1% Long Return +2.1% Short Return -
Average Return
7d -10.9%
30d -3.0%
90d +5.9%
Visual Insights Log in to see ideas
Result
Result
Sort
Theme Stance
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
BNTX 1ST BioNTech... BioNTech SE America...
Long
May 31
$95.95
+2.1%
ASCO 2026 data showed 72.7% objective response rate in squamous NSCLC and 63.6% in nonsquamous, with low severe toxicity (4.7% immune-related adverse events). FDA fast track potential via PFS endpoint change. The market has not priced in the magnitude of this data; a gap up Monday is expected, followed by institutional upgrades (UBS $135 PT). Short-dated and medium-dated call options offer asymmetric upside. Author is heavily long BNTX options across June/July/September expiries, betting on an immediate catalyst-driven rally and continued positive momentum from deep oncology pipeline. Phase 3 data could fail or show inferiority to Keytruda; safety signals (bleeding events) could re-emerge; overall survival data may disappoint if FDA insists on OS endpoint; market sentiment shift away from biotech.
ASCO 2026 data showed 72.7% objective response rate in squamous NSCLC and 63.6% in nonsquamous, with low severe toxicity (4.7% immune-related adverse events). FDA fast track potential via PFS endpoint change. The market has not priced in the magnitude of this data; a gap up Monday is expected, followed by institutional upgrades (UBS $135 PT). Short-dated and medium-dated call options offer asymmetric upside. Author is heavily long BNTX options across June/July/September expiries, betting on an immediate catalyst-driven rally and continued positive momentum from deep oncology pipeline. Phase 3 data could fail or show inferiority to Keytruda; safety signals (bleeding events) could re-emerge; overall survival data may disappoint if FDA insists on OS endpoint; market sentiment shift away from biotech.
Pharma & Biotech
REDDIT
Showing 1 of 1 calls · sorted by mentions

u/akavaev has 1 trade ideas tracked on Buzzberg across 1 tickers since May 2026. Most covered: BNTX.

Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology